Oncology News | pharmaphorum

News

Janssen J&J Johnson and Johnson pharmaceutical companies

J&J gets first approval for multiple myeloma bispecific Tecv...

Johnson & Johnson has its first worldwide regulatory approval – in the EU – for Tecvayli, one of two much-anticipated bispecific antibodies the drugmaker has developed for patients with

News

Doctor using mobile smart phone, work on laptop computer with notebook and medical stethoscope on the desk at office. Telehealth, telemedicine or medic tech concept.

NCI sets aside $23m to research telehealth in cancer care

The National Cancer Institute (NCI) in the US has said it will make $23 million available to four academic institutions over the next five years to study the role of telehealth for cancer p

News

Oncopeptides gets EU nod for myeloma drug Pepaxti ahead of U...

The European Commission has approved Oncopeptides' Pepaxti in combination with dexamethasone for multiple myeloma patients with so-called triple class refractory disease – in other words th

News

Troubled Nordic Nanovector "exploring strategic options"

Reeling from the recent failure of its lead product in a pivotal trial, Nordic Nanovector has formally started a restructuring process and called in investment bank Carnegie to help explore

News

Atomwise founders Abraham Heifets and Izar Wallach.

Diving deeper into AI discovery, Sanofi signs 5-drug deal wi...

Sanofi is tapping San Francisco-based Atomwise for a new AI-fuelled drug discovery deal, paying $20 million for five new drug targets — and possibly spending more than a billion in mileston

News

End of the line for Sanofi's SERD amcenestrant as it fails f...

Sanofi has called time on breast cancer candidate amcenestrant – at one time one of its top pipeline prospects – after it missed the mark in another clinical trial.

J&J gets first approval for multiple myeloma bispecific Tecv...

NCI sets aside $23m to research telehealth in cancer care

Oncopeptides gets EU nod for myeloma drug Pepaxti ahead of U...

Troubled Nordic Nanovector "exploring strategic options"

Diving deeper into AI discovery, Sanofi signs 5-drug deal wi...

End of the line for Sanofi's SERD amcenestrant as it fails f...

Senju launches first-in-class dry eye disease drug in Japan

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks